Connection

Contact Us
If you have any questions or feedback please contact us.

Search Results to David Ross Camidge

This is a "connection" page, showing the details of why an item matched the keywords from your search.

Search Results

Camidge, David

One or more keywords matched the following items that are connected to Camidge, David

Item Type	Name
Academic Article	Cutaneous B cell lymphoma arising from a chronically inflamed sebaceous cyst.
Academic Article	Plucked human hair as a tissue in which to assess pharmacodynamic end points during drug development studies.
Academic Article	Assessing proliferation, cell-cycle arrest and apoptotic end points in human buccal punch biopsies for use as pharmacodynamic biomarkers in drug development.
Academic Article	Factors determining the optimal body site and method for obtaining punch biopsies of human skin as a tissue in which to assess pharmacodynamic and pharmacokinetic endpoints in drug development studies.
Academic Article	A first-in-man phase I tolerability and pharmacokinetic study of the cyclin-dependent kinase-inhibitor AZD5438 in healthy male volunteers.
Academic Article	From radiotherapy to Targeted therapy: 20 years in the management of non-small-cell lung cancer.
Academic Article	The potential of death receptor 4- and 5-directed therapies in the treatment of lung cancer.
Academic Article	Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer.
Academic Article	Apomab: an agonist monoclonal antibody directed against Death Receptor 5/TRAIL-Receptor 2 for use in the treatment of solid tumors.
Academic Article	The insulin-like growth factor pathway in lung cancer.
Academic Article	Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis.
Academic Article	Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study.
Academic Article	ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer.
Academic Article	Mitotic inhibitors.
Academic Article	New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer.
Academic Article	The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer.
Academic Article	Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
Academic Article	Cell cycle-associated kinases as targets for therapy in lung cancer.
Academic Article	Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer.
Academic Article	Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment.
Academic Article	Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors.
Academic Article	Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.
Academic Article	A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer.
Academic Article	Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.
Academic Article	A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer.
Academic Article	Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer.
Academic Article	Have mutation, will travel: utilizing online patient communities and new trial strategies to optimize clinical research in the era of molecularly diverse oncology.
Academic Article	A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer.
Academic Article	The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers.
Academic Article	Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.
Academic Article	Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer.
Academic Article	Treating ALK-positive lung cancer--early successes and future challenges.
Academic Article	A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors.
Academic Article	Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma.
Academic Article	First-in-human phase I trial of two schedules of OSI-930, a novel multikinase inhibitor, incorporating translational proof-of-mechanism studies.
Academic Article	Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer.
Academic Article	Characteristics of lung cancers harboring NRAS mutations.
Academic Article	Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer.
Academic Article	Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients.
Academic Article	Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma.
Academic Article	Response to crizotinib rechallenge after initial progression and intervening chemotherapy in ALK lung cancer.
Academic Article	Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
Academic Article	A phase I pharmacodynamic study of the effects of the cyclin-dependent kinase-inhibitor AZD5438 on cell cycle markers within the buccal mucosa, plucked scalp hairs and peripheral blood mononucleocytes of healthy male volunteers.
Academic Article	Factors affecting the mesothelioma detection rate within national and international epidemiological studies: insights from Scottish linked cancer registry-mortality data.
Academic Article	Dynamic and modern: bringing the ethics of phase I trials up to date.
Academic Article	Economic evaluation of fulvestrant as an extra step in the treatment sequence for ER-positive advanced breast cancer.
Academic Article	Surprised by stage III: unexpected N2 lymph node involvement found during surgery for early-stage NSCLC.
Academic Article	The rationale and development of therapeutic insulin-like growth factor axis inhibition for lung and other cancers.
Academic Article	Hospital admissions and deaths relating to deliberate self-harm and accidents within 5 years of a cancer diagnosis: a national study in Scotland, UK.
Academic Article	A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors.
Academic Article	A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer.
Academic Article	A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies.
Academic Article	Targeted manipulation of apoptosis in cancer treatment.
Academic Article	Is FISH floating or still swimming in the lung cancer ocean?
Academic Article	Finding ALK-positive lung cancer: what are we really looking for?
Academic Article	Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed.
Academic Article	Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.
Academic Article	Molecular origins of lung cancer: prospects for personalized prevention and therapy.
Academic Article	Preclinical and clinical estimates of the basal apoptotic rate of a cancer predict the amount of apoptosis induced by subsequent proapoptotic stimuli.
Academic Article	Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors.
Academic Article	Impact of induction chemotherapy on estimated risk of radiation pneumonitis in small cell lung cancer.
Academic Article	A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer.
Academic Article	Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.
Academic Article	Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer.
Academic Article	Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer.
Academic Article	Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.
Academic Article	Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.
Academic Article	Targeting ALK, ROS1, and BRAF kinases.
Academic Article	Apoptotic pathway manipulation.
Academic Article	The intersection between cannabis and cancer in the United States.
Academic Article	A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer.
Academic Article	Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer.
Academic Article	Crizotinib for the treatment of patients with advanced non-small cell lung cancer.
Academic Article	Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.
Academic Article	Taking aim at ALK across the blood-brain barrier.
Concept	Early Detection of Cancer
Concept	Central Nervous System Neoplasms
Concept	Pleural Neoplasms
Concept	Tumor Burden
Concept	Brain Neoplasms
Concept	Lung Neoplasms
Concept	Tumor Suppressor Protein p53
Concept	Neoplasm Metastasis
Concept	Urinary Bladder Neoplasms
Concept	Thymus Neoplasms
Concept	Meningeal Neoplasms
Concept	DNA, Neoplasm
Concept	Biomarkers, Tumor
Concept	Antigens, Neoplasm
Concept	Thoracic Neoplasms
Concept	Colorectal Neoplasms
Concept	Neoplasm Proteins
Concept	Neoplasm Staging
Concept	Kidney Neoplasms
Concept	Drug Resistance, Neoplasm
Concept	Breast Neoplasms
Concept	Tumor Cells, Cultured
Concept	Head and Neck Neoplasms
Concept	Lymphocytes, Tumor-Infiltrating
Concept	Neoplasms
Concept	Skin Neoplasms
Concept	Cell Line, Tumor
Concept	Neoplasm Recurrence, Local
Concept	Peritoneal Neoplasms
Concept	Liver Neoplasms
Academic Article	Icotinib: kick-starting the Chinese anticancer drug industry.
Academic Article	Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group.
Academic Article	Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group.
Academic Article	Clinical benefit from pemetrexed before and after crizotinib exposure and from crizotinib before and after pemetrexed exposure in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer.
Academic Article	Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer.
Academic Article	Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer: implications for ALK inhibitor therapy.
Academic Article	Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib.
Academic Article	A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer.
Academic Article	Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib.
Academic Article	A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.
Academic Article	Atypical negative ALK break-apart FISH harboring a crizotinib-responsive ALK rearrangement in non-small-cell lung cancer.
Academic Article	Phase II trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer.
Academic Article	Ceritinib in ALK-rearranged non-small-cell lung cancer.
Academic Article	Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.
Academic Article	FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies.
Academic Article	A randomized, phase 2 trial of Docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic non-small-cell lung cancer.
Academic Article	Acquired resistance to TKIs in solid tumours: learning from lung cancer.
Academic Article	Realizing the potential of plasma genotyping in an age of genotype-directed therapies.
Academic Article	Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations.
Academic Article	The impact of socioeconomic status on access to cancer clinical trials.
Academic Article	NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies.
Academic Article	Crizotinib in ROS1-rearranged non-small-cell lung cancer.
Academic Article	Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer.
Academic Article	Crizotinib effects on creatinine and non-creatinine-based measures of glomerular filtration rate.
Academic Article	Non-small cell lung cancer, version 1.2015.
Academic Article	A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small-cell lung cancer.
Academic Article	Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
Academic Article	Buyer beware: understanding the assumptions behind health economic assessments in personalized cancer care.
Academic Article	Targeted therapy vs chemotherapy: which has had more impact on survival in lung cancer? Does targeted therapy make patients live longer? Hard to prove, but impossible to ignore.
Academic Article	Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer.
Academic Article	Rociletinib in EGFR-mutated non-small-cell lung cancer.
Academic Article	Non-Small Cell Lung Cancer, Version 6.2015.
Academic Article	Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.
Academic Article	Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors.
Academic Article	Response assessment criteria for brain metastases: proposal from the RANO group.
Academic Article	PROFILE 1014: lessons for the new era of lung cancer clinical research.
Academic Article	Waxing and Waning of MET Amplification in EGFR-Mutated NSCLC in Response to the Presence and Absence of Erlotinib Selection Pressure.
Academic Article	Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis.
Academic Article	Downstaging of Non-Small-Cell Lung Cancer Through Identification of Reversible Drug Toxicity.
Academic Article	Cystic Brain Metastases Occurring in Anaplastic Lymphoma Kinase Gene Rearranged Non-Small-Cell Lung Cancer Patients Receiving Crizotinib.
Academic Article	Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.
Academic Article	A Brief Report of the Status of Central Nervous System Metastasis Enrollment Criteria for Advanced Non-Small Cell Lung Cancer Clinical Trials: A Review of the ClinicalTrials.gov Trial Registry.
Academic Article	NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016.
Academic Article	Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non-Small Cell Lung Cancer: Results of a Phase I Study.
Academic Article	Malignant pleural disease is highly associated with subsequent peritoneal metastasis in patients with stage IV non-small cell lung cancer independent of oncogene status.
Academic Article	Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686).
Academic Article	Update to Rociletinib Data with the RECIST Confirmed Response Rate.
Academic Article	Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.
Academic Article	Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.
Academic Article	NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016.
Academic Article	An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer.
Academic Article	A Primer on Health Economic Evaluations in Thoracic Oncology.
Academic Article	Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis.
Academic Article	Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK.
Academic Article	A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma.
Academic Article	Transient Asymptomatic Pulmonary Opacities Occurring during Osimertinib Treatment.
Academic Article	Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
Academic Article	Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study.
Academic Article	Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer.
Academic Article	Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.
Academic Article	Responses to Crizotinib Can Occur in High-Level MET-Amplified Non-Small Cell Lung Cancer Independent of MET Exon 14 Alterations.
Academic Article	Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
Academic Article	Survival of Asian Females With Advanced Lung Cancer in the Era of Tyrosine Kinase Inhibitor Therapy.
Academic Article	Management of Brain Metastases in Tyrosine Kinase Inhibitor-Na?ve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.
Academic Article	The Impact of Postoperative Radiotherapy for Thymoma and Thymic Carcinoma.
Academic Article	Tolerable and Effective Combination of Full-Dose Crizotinib and Osimertinib Targeting MET Amplification Sequentially Emerging after T790M Positivity in EGFR-Mutant Non-Small Cell Lung Cancer.
Academic Article	Drinking Not Drowning: How to Deal With the Deluge of Potential Predictive Biomarker Approaches in Non-Small-Cell Lung Cancer.
Academic Article	Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
Academic Article	Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria.
Academic Article	Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan.
Academic Article	Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.
Academic Article	Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan.
Academic Article	Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung.
Academic Article	Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.
Academic Article	A phase 2, open-label, multi-center study of amuvatinib in combination with platinum etoposide chemotherapy in platinum-refractory small cell lung cancer patients.
Academic Article	Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma.
Academic Article	KEYNOTE-028: how do we use immunotherapy in small cell lung cancer?
Academic Article	Excellent Outcomes with Radiosurgery for Multiple?Brain Metastases in ALK and EGFR Driven?Non-Small Cell Lung Cancer.
Academic Article	Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group.
Academic Article	Lung cancer's real adjuvant EGFR targeted therapy questions.
Academic Article	Dramatic Response to Crizotinib in a Patient with Lung Cancer Positive for an HLA-DRB1-MET Gene Fusion.
Academic Article	Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer.
Academic Article	Targeting ALK in inflammatory myofibroblastic tumours.
Academic Article	Radiosurgery alone is associated with favorable outcomes for brain metastases from small-cell lung cancer.
Academic Article	Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials.
Academic Article	Phase Ib Study of High-dose Intermittent Afatinib in Patients With Advanced Solid Tumors.
Academic Article	The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib.
Academic Article	Correlation of extent of ALK FISH positivity and crizotinib efficacy in three prospective studies of ALK-positive patients with non-small-cell lung cancer.
Academic Article	Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers.
Academic Article	Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer.
Academic Article	Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma.
Academic Article	Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.
Academic Article	First-line Chemotherapy Responsiveness and Patterns of Metastatic Spread Identify Clinical Syndromes Present Within Advanced KRAS Mutant Non-Small-cell Lung Cancer With Different Prognostic Significance.
Academic Article	Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study.
Academic Article	Antibody drug conjugates in thoracic malignancies.
Academic Article	Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
Academic Article	Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor.
Academic Article	Preselection of Lung Cancer Cases Using FGFR1 mRNA and Gene Copy Number for Treatment With Ponatinib.
Academic Article	A Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors.
Academic Article	Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Academic Article	ROS1 Gene Rearrangements Are Associated With an Elevated Risk of Peridiagnosis Thromboembolic Events.
Academic Article	Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
Academic Article	Lorlatinib Salvages CNS Relapse in an ALK-Positive Non-Small-Cell Lung Cancer Patient Previously Treated With Crizotinib and High-Dose Brigatinib.
Academic Article	HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib.
Academic Article	Natural History and Factors Associated with Overall Survival in Stage IV ALK-Rearranged Non-Small Cell Lung Cancer.
Academic Article	DNA-Based versus RNA-Based Detection of MET Exon 14 Skipping Events in Lung?Cancer.
Academic Article	Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC.
Academic Article	Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer.
Academic Article	MET Copy Number as a Secondary Driver of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in EGFR-Mutant Non-Small-Cell Lung Cancer.
Academic Article	Renal Effects of Crizotinib in Patients With ALK-Positive Advanced NSCLC.
Academic Article	ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.
Academic Article	Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib?in?Untreated ALK-Positive Advanced Non-Small Cell?Lung Cancer in the Global Phase III ALEX Study.
Academic Article	Searching for a chemoimmunotherapy signal in patients with non-small-cell lung cancer and EGFR mutations.
Academic Article	Is long-term survival possible for patients with stage IV ALK+ non-small cell lung cancer?
Academic Article	Docetaxel-induced radiation recall dermatitis and successful rechallenge without recurrence.
Concept	Circulating Tumor DNA
Concept	Tumor Microenvironment
Concept	Response Evaluation Criteria in Solid Tumors
Academic Article	Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001.
Academic Article	A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung Cancer.
Academic Article	Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study.
Academic Article	Management Strategies for Early-Onset Pulmonary Events Associated with Brigatinib.
Academic Article	Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
Academic Article	Impact of Radiation Dose to the Host Immune System on Tumor Control and Survival for Stage III Non-Small Cell Lung Cancer Treated with Definitive Radiation Therapy.
Academic Article	Detection of NRG1 Fusions in Solid Tumors: Rare Gold?
Academic Article	Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis.
Academic Article	Authors' Reply.
Academic Article	A rational approach to the development of drug combinations in thoracic oncology.
Academic Article	Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer.
Academic Article	Untapped potential: recognising CNS opportunities in early oncology drug development.
Academic Article	Next-generation ALK inhibitors: is the median the message?
Academic Article	Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort.
Academic Article	Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial.
Academic Article	Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer.
Academic Article	Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer.
Academic Article	Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer.
Academic Article	Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration.
Academic Article	Cecal Volvulus as a Rare Complication of Osimertinib Dosed at 160 mg in Patients With EGFR-Mutant Non-small Cell Lung Cancer.
Academic Article	Variation in Toxicity Reporting Methods for Early Phase Lung Cancer Treatment Trials at Oncology Conferences.
Academic Article	Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study.
Academic Article	Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer.
Academic Article	Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial.
Academic Article	Radiosurgery for Small-Cell Brain Metastases: Challenging the Last Bastion of Preferential Whole-Brain Radiotherapy Delivery.
Academic Article	GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients.
Academic Article	Prospective Clinical Validation of the InVisionFirst-Lung Circulating Tumor DNA Assay for Molecular Profiling of Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Academic Article	Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial.
Academic Article	Blood-Based Biomarkers for Predicting Immunotherapy Benefit in Lung Cancer.
Academic Article	Comparative effectiveness of nivolumab versus standard of care for third-line patients with small-cell lung cancer.
Academic Article	Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903).
Academic Article	Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer.
Academic Article	Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial.
Academic Article	Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs.
Academic Article	Crizotinib in Patients With MET-Amplified NSCLC.
Academic Article	Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naive ALK?+?non-small cell lung cancer (ALTA-1L).
Academic Article	Lorlatinib Should Not be Considered as the Preferred First-Line Option in Patients With Advanced ALK Rearranged NSCLC.
Academic Article	Increasing Transparency in Author Contributions to Manuscripts: Enhanced Policy on Ghost and Honorary Authorships.
Academic Article	Race and ethnicity representation in clinical trials: findings from a literature review of Phase I oncology trials.
Academic Article	Early Alectinib Resistance From MET Amplification in ALK-Rearranged NSCLC: Response to Crizotinib with Re-Response to Alectinib and Crizotinib.
Academic Article	Clinicopathologic Features and Response to Therapy of NRG1 Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry.
Grant	A randomized phase II study of erlotinib with or without the anti-IGF-1R monoclon
Academic Article	A Phase 1 Study Evaluating Rovalpituzumab Tesirine in Frontline Treatment of Patients With Extensive-Stage SCLC.
Academic Article	Central Nervous System Response to Selpercartinib in Patient With RET-rearranged Non-small Cell Lung Cancer After Developing Leptomeningeal Disease on Pralsetinib.
Academic Article	A narrative review of primary research endpoints of neoadjuvant therapy for lung cancer: past, present and future.
Academic Article	Real-world insights into patients with advanced NSCLC and MET alterations.
Academic Article	First-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid Tumors.
Academic Article	Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma.
Academic Article	Brain Metastases in EGFR- and ALK-Positive NSCLC: Outcomes of Central Nervous System-Penetrant Tyrosine Kinase Inhibitors Alone Versus in Combination With Radiation.
Academic Article	Cost-effectiveness of nivolumab monotherapy in the third-line treatment of small cell lung cancer.
Academic Article	Tumor Shrinkage With Combination of Alectinib and Trastuzumab in a Patient With ALK-Rearranged Non-small Cell Lung Cancer Harboring HER2-Amplification as an Acquired Resistance Mechanism to ALK Inhibitor Therapy.
Academic Article	Genetic landscape of patients with ALK-rearranged non-small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study.
Academic Article	Managing Central Nervous System Spread of Lung Cancer: The State of the Art.
Academic Article	Population pharmacokinetic and exposure-response analyses from ALTA-1L: Model-based analyses supporting the brigatinib dose in ALK-positive NSCLC.
Academic Article	In Response to: "Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal Endpoint?"
Academic Article	Case Report: Significant Clinical Benefit From Pemetrexed-Based Therapy in ROS1- and ALK-rearranged Lung Cancer With Adenosquamous Histology.
Academic Article	EGFR Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase Inhibitor.
Academic Article	Effectiveness of crizotinib versus entrectinib in ROS1-positive non-small-cell lung cancer using clinical and real-world data.
Academic Article	The Magic of ADAURA?
Academic Article	Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non-small Cell Lung Cancer in the Global Phase III ALEX Trial.
Academic Article	Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review.
Academic Article	Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.
Academic Article	COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer.
Academic Article	A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib.
Academic Article	Extending Our Reach: Expanding Enrollment in Brain Metastases and Primary Brain Tumor Clinical Trials.
Academic Article	Association of anticoagulant use with clinical outcomes from crizotinib in ALK- and ROS1-rearranged advanced non-small cell lung cancers: A retrospective analysis of PROFILE 1001.
Academic Article	Indirect comparisons of brigatinib and alectinib for front-line ALK-positive non-small-cell lung cancer.
Academic Article	Quantifying The Medical Impact of A Missed Diagnosis of Non-Small Cell Lung Cancer on Chest Imaging.
Academic Article	First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors.
Academic Article	Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States.
Academic Article	Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinase-positive non-small cell lung cancer using data from ALEX and final results from ALTA-1L.
Academic Article	Pregnancy and Pathways to Motherhood in Oncogene-driven Lung Cancer: A Single Institution Experience.
Academic Article	Oncogene Overlap Analysis of Circulating Cell-free Tumor DNA to Explore the Appropriate Criteria for Defining MET Copy Number-Driven Lung Cancer.
Academic Article	NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations.
Academic Article	Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study.
Academic Article	The Effect of Intrathoracic Lesion Location on Initial Tyrosine Kinase Inhibitor Response in Advanced Oncogene-Addicted Non-Small Cell Lung Cancer: A Comparison Between RECIST 1.1 and a Novel Method of Response Assessment (MAX).
Academic Article	PD-1/PD-L1 inhibitor activity in patients with gene-rearrangement positive non-small cell lung cancer-an IMMUNOTARGET case series.
Academic Article	CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report.
Academic Article	Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer.
Academic Article	A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer.
Academic Article	Safety and Efficacy Results From iSABR, a Phase 1 Study of Stereotactic ABlative Radiotherapy in Combination With Durvalumab for Early-Stage Medically Inoperable Non-Small Cell Lung Cancer.
Academic Article	Comparison of first-line radiosurgery for small-cell and non-small cell lung cancer brain metastases (CROSS-FIRE).
Academic Article	Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1-Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial.
Academic Article	Editorial Related to Leeuw et?al.: The Evolution of Expectations: How Our Views On "Acceptable" Toxicities Are Changing With Prolonged Lung Cancer Treatments.
Academic Article	Q-TWiST analysis of survival benefits with brigatinib versus crizotinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer based on results of the ALTA-1L trial.
Academic Article	CSF Cytology Identifies Mechanisms of Tyrosine Kinase Inhibitor Resistance in Patient With EGFR-Mutated NSCLC With CNS Progression.
Academic Article	Trial Design and Optimal Determination of CNS Activity of Small Molecule Targeted Therapy in NSCLC.
Academic Article	Lung Cancer Oncogene-Directed Therapy, Fertility, and Pregnancy.
Academic Article	Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
Academic Article	First-in-Human Dose-Escalation Study of the Novel Oral Depsipeptide Class I-Targeting HDAC Inhibitor Bocodepsin (OKI-179) in Patients with Advanced Solid Tumors.

Search Criteria

Neoplasms